Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 23;11:5928. doi: 10.1038/s41467-020-19774-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — a The OS in all patients who received Sino 19 infusion, the median OS was 415.0 days (95% CI: 15.5–814.5). The rate of OS at 1 year was 53.0% (95% CI: 37.2–68.8). b The OS between pediatric and adult cohort showed no significant difference (p = 0.329). c The OS in patients with EMDs (CNS involvement only or EMDs other than CNS) was lower than that in patients without EMDs (p = 0.021 and 0.003), respectively, but no significant difference was observed between the two EMDs subgroups (p = 0.905). d The OS in patients with or without higher Tregs, 1-year OS rate was 29.3% vs. 64.2% (p = 0.011). e The OS in patients with or without high-risk cytogenetic factors, 1-year OS rate was 34.3% vs. 66.7% (p = 0.047). Patients who were bridged to allo-HSCT were excluded when we analyzed the influence of patient characteristics on OS (c–e). b–e were performed by the Kaplan–Meier approach and used a two-sided log-rank test. Source data is provided as a Source Data file or available at 10.6084/m9.figshare.13136078.v1.